Pfenex snags a $143.5M anthrax contract with the feds

Biosimilars outfit Pfenex ($PFNX) signed a deal worth as much as $143.5 million to develop an anthrax vaccine for the U.S. government's biomedical research division. Under the agreement, Pfenex will press forward with Px563L, an anthrax candidate that uses recombinant antigens to protect the body against viral infection. The U.S.'s Biomedical Advanced Research and Development Authority (BARDA) has committed to funding a Phase Ia study, promising funds for Phase II if things go according to plan. And if Px563L is a success, Pfenex believes it could be added to the U.S. stockpile of biodefense treatments. More

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.